Table 2.
Clinicopathologic characteristics of patients according to breast cancer phenotype
| Parameter | Total (n = 406) (%) | Luminal A (n = 168) (%) | Luminal B (n = 87) (%) | HER-2 (n = 32) (%) | TNBC (n = 119) (%) | P-value |
|---|---|---|---|---|---|---|
| Age (years) | 0.284 | |||||
| ≤ 50 | 229 (56.4) | 93 (55.4) | 55 (63.2) | 14 (43.8) | 67 (56.3) | |
| > 50 | 177 (43.6) | 75 (44.6) | 32 (36.8) | 18 (56.2) | 52 (43.6) | |
| Histologic grade | < 0.001 | |||||
| I/II | 265 (65.3) | 151 (89.9) | 56 (64.4) | 15 (46.9) | 43 (36.1) | |
| III | 141 (34.7) | 17 (10.1) | 31 (35.6) | 17 (53.1) | 76 (63.9) | |
| Tumor stage | 0.022 | |||||
| T1 | 203 (50.0) | 98 (58.3) | 43 (49.4) | 14 (43.8) | 48 (40.3) | |
| T2/T3 | 203 (50.0) | 70 (41.7) | 44 (50.6) | 18 (56.2) | 71 (59.7) | |
| Nodal metastasis | 0.426 | |||||
| Absent | 250 (61.6) | 101 (60.1) | 49 (56.3) | 20 (62.5) | 80 (67.2) | |
| Present | 156 (38.4) | 67 (39.9) | 38 (43.7) | 12 (37.5) | 39 (32.8) | |
| Estrogen receptor status | < 0.001 | |||||
| Negative | 156 (38.4) | 2 (1.2) | 3 (3.4) | 32 (100.0) | 119 (100.0) | |
| Positive | 250 (61.6) | 166 (98.8) | 84 (96.6) | 0 (0.0) | 0 (0.0) | |
| Progesterone receptor status | < 0.001 | |||||
| Negative | 201 (49.5) | 22 (13.1) | 28 (32.2) | 32 (100.0) | 119 (100.0) | |
| Positive | 205 (50.5) | 146 (86.9) | 59 (67.8) | 0 (0.0) | 0 (0.0) | |
| HER-2 status | < 0.001 | |||||
| Negative | 331 (81.5) | 168 (100.0) | 44 (50.6) | 0 (0.0) | 119 (100.0) | |
| Positive | 75 (18.5) | 0 (0.0) | 43 (49.4) | 32 (100.0) | 0 (0.0) | |
| Ki-67 LI (%) | < 0.001 | |||||
| ≤ 14 | 229 (56.4) | 168 (100.0) | 26 (29.9) | 16 (50.0) | 229 (56.4) | |
| > 14 | 177 (43.6) | 0 (0.0) | 61 (70.1) | 16 (50.0) | 177 (43.6) | |
| Tumor recurrence | 41 (10.1) | 10 (6.0) | 8 (9.2) | 6 (18.8) | 17 (14.3) | 0.042 |
| No. of patient deaths | 43 (10.6) | 10 (6.0) | 9 (10.3) | 7 (21.9) | 17 (14.3) | 0.020 |
TNBC, triple negative breast cancer.